Earnings Call · Q2 FY2022·2021-11-10

Q2 22EPS +6.67%·Rev n/aQ1 22EPS +33.33%·Rev n/aQ4 21EPS -100.00%*·Rev n/aQ3 21EPS -31.25%·Rev n/a⚠ consensus missing

Vistagen Therapeutics, Inc. VTGN

Mark Flather — Vice President of Investor Relations

Shawn Singh — Chief Executive Officer

Jerry Dotson — Chief Financial Officer

+4.0%1d on move date+4.0% vs SPY3d−4.4%5d−3.1%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VTGN calls or request research access.

More VTGN calls Browse calls Request research access